STERISHEALTHCARE Products
Mumbai info@sterispharma.com
918824175417
Chat with us  

Chat with us on WhatsApp

×
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
Home Products ALFUGEM T 2.5/10
COD not available
UROLOGYRANGE by alfuzosin and tadalafil

ALFUGEM T 2.5/10

INR 217 INR 310
You Save: INR 93 (30%)
Check On
Share with
Check On
Share this on :

Description

Product details

ALFUGEM T 2.5/10 is a scientifically formulated dual-action oral tablet that combines Alfuzosin 2.5 mg and Tadalafil 10 mg. This unique combination is primarily used for the treatment of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) in men. By blending a selective alpha-blocker (Alfuzosin) with a phosphodiesterase-5 (PDE5) inhibitor (Tadalafil), ALFUGEM T 2.5/10 offers an effective solution for patients who suffer from both urological conditions. The combination of alfuzosin and tadalafil has been shown to have an additive relaxant effect on human detrusor and prostatic tissues in vitro, enhancing urinary flow and improving sexual function. What is ALFUGEM T 2.5/10? ALFUGEM T 2.5/10 is a fixed-dose combination tablet that contains two active ingredients: Alfuzosin (2.5 mg) – an alpha-1 adrenergic receptor blocker that relaxes the muscles in the prostate and bladder neck. Tadalafil (10 mg) – a PDE5 inhibitor that increases blood flow to the penis and also helps relax the smooth muscles in the prostate and bladder. Together, they help relieve lower urinary tract symptoms (LUTS) associated with BPH and improve erectile function in men. Uses of ALFUGEM T 2.5/10: Treatment of Benign Prostatic Hyperplasia (BPH) Relief of lower urinary tract symptoms (LUTS) such as weak stream, urgency, and incomplete bladder emptying Management of erectile dysfunction (ED) in men May be beneficial for patients with both BPH and ED as a once-daily treatment How Does ALFUGEM T 2.5/10 Work? Alfuzosin works by blocking alpha-1 receptors in the prostate and bladder, leading to relaxation of smooth muscle and improved urine flow. Tadalafil enhances nitric oxide activity, leading to vasodilation in the penile tissues and also relaxes the lower urinary tract muscles. The additive relaxant effect of this combination on the prostate and bladder tissues helps improve both urinary and sexual symptoms. Side Effects of ALFUGEM T 2.5/10: Like all medications, ALFUGEM T 2.5/10 may cause some side effects. Common side effects include: Dizziness or lightheadedness Headache Back pain or muscle aches Nasal congestion Indigestion Flushing Low blood pressure (hypotension) in some cases Rare but serious side effects may include: Fainting or severe dizziness Priapism (prolonged or painful erection) Vision changes or sudden vision loss Chest pain or irregular heartbeat Precautions Before Using ALFUGEM T 2.5/10: Consult your doctor before use if you have a history of heart disease, liver/kidney problems, or hypotension. Avoid activities like driving or operating machinery if you feel dizzy after taking the tablet. Do not take with other PDE5 inhibitors or alpha-blockers unless prescribed. Limit alcohol intake, as it can increase the risk of dizziness or low blood pressure. Not recommended for use in women or children. Drug Interactions – What Drugs Interact with ALFUGEM T 2.5/10? Certain drugs may interact with ALFUGEM T 2.5/10 and affect its effectiveness or increase the risk of side effects: Avoid or use with caution: Nitrates (e.g., nitroglycerin) – can cause dangerous drops in blood pressure Other alpha-blockers – increased risk of hypotension Antifungals (e.g., ketoconazole, itraconazole) HIV protease inhibitors (e.g., ritonavir) Antibiotics (e.g., erythromycin, clarithromycin) Blood pressure medications – may enhance hypotensive effect Grapefruit juice – can alter the drug metabolism Always inform your doctor about all the medications and supplements you are taking. Conclusion: ALFUGEM T 2.5/10 offers a comprehensive dual-action approach to managing two common male conditions – BPH and ED. With the clinically proven benefits of alfuzosin and tadalafil, this medication not only improves urinary flow and relieves prostate-related discomfort but also enhances sexual performance. Its synergistic relaxant effect on the bladder, prostate, and penile tissues makes it an ideal solution for men looking for convenience, efficacy, and improved quality of life. Always follow your healthcare provider’s instructions for safe and effective use.

  • Filter tags

Other Products

Related Products

GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control. It is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes. Mechanism of Action The therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism: 1. Glimepiride (1 mg) – Sulfonylurea Stimulates insulin secretion by activating pancreatic beta cells. Provides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas. Helps reduce both fasting and postprandial glucose levels. 2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor Delays the breakdown and absorption of carbohydrates in the intestine. Minimizes post-meal glucose spikes (PPBG). Acts locally in the gut and has minimal systemic absorption, which reduces systemic side effects. 3. Metformin Hydrochloride SR (500 mg) – Biguanide Decreases hepatic glucose production (gluconeogenesis). Improves peripheral insulin sensitivity, enhancing glucose uptake in muscles. Does not cause hypoglycemia on its own. The sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects. Indications GLIMITERIS MV1 0.2 is indicated for: Adults with Type 2 Diabetes Mellitus. Patients inadequately controlled with monotherapy or dual therapy. Management of fasting and postprandial hyperglycemia. Long-term HbA1c reduction as part of a comprehensive diabetes care plan. Key Benefits ✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels. ✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges. ✅ Reduced Pill Burden – Combines three medicines into a single tablet. ✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect. ✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain. ✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort. Dosage and Administration Recommended dose: One tablet once or twice daily with meals, or as directed by the physician. Administration tips: Take with the first bite of a main meal to maximize Voglibose’s effect. Swallow whole with water; do not crush or chew the SR tablet. Dose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function. Contraindications GLIMITERIS MV1 0.2 is not suitable for patients with: Type 1 diabetes or diabetic ketoacidosis. Severe renal impairment (eGFR <30 mL/min/1.73 m²). Hepatic dysfunction. Severe gastrointestinal diseases. History of lactic acidosis. Hypersensitivity to Glimepiride, Voglibose, or Metformin. Pregnancy and lactation (unless strictly advised by a physician). Warnings and Precautions Hypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals. Lactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential. GI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary). Vitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption. Liver and Kidney Function: Regular monitoring is recommended for safe long-term use. Adverse Effects Common: Glimepiride: Mild hypoglycemia, dizziness, slight weight gain. Voglibose: Gas, abdominal discomfort, mild diarrhea. Metformin SR: Nausea, bloating, metallic taste, loose stools. Rare but Serious: Lactic acidosis (from Metformin). Severe hypoglycemia (especially if meals are skipped). Allergic reactions such as rash, itching, or swelling. Elevated liver enzymes. Seek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur. Drug Interactions Increased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas. Reduced Metformin efficacy: With corticosteroids, estrogens, and diuretics. Lactic acidosis risk: Higher with alcohol or iodinated contrast agents.
View Details
Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg

INR263

BUDESHINE F 400 CAP - This is a combination inhalation therapy used in the management of asthma and Chronic Obstructive Pulmonary Disease (COPD). Mechanism of Action: Formoterol Fumarate: A long-acting β2-adrenergic agonist (LABA) that relaxes airway smooth muscles, providing rapid and sustained bronchodilation. Budesonide: An inhaled corticosteroid (ICS) that reduces airway inflammation, swelling, and mucus production. Together, they offer dual action—quick relief of bronchospasm and long-term control of airway inflammation. Indications: Asthma (for patients not controlled adequately with inhaled corticosteroids alone). Chronic Obstructive Pulmonary Disease (COPD) with reversible airway obstruction. Prevention of asthma attacks and reduction of COPD exacerbations. Key Benefits: Provides fast and sustained relief from breathing difficulty. Controls both inflammation and bronchospasm. Reduces the frequency and severity of asthma/COPD flare-ups. Improves overall lung function and quality of life. Dosage and Administration: Administered via inhalation as directed by a physician. Dose depends on the severity of disease and patient response. Regular use is required for effective control—not for acute asthma attacks. (Exact dosing schedule to be prescribed by the doctor.)
View Details
Formoterol Fumarate Dihydrate Ip 6 mcg & Budesonide IP 400 mcg

INR238

KEYPROFEN DT is a fast-acting nonsteroidal anti-inflammatory drug (NSAID) used to relieve moderate pain and inflammation. Its dispersible tablet form ensures quick dissolution and faster pain relief, making it convenient for oral administration. Ideal for managing post-operative pain, musculoskeletal discomfort, and other short-term pain conditions.
View Details
ketorolac tromethamine dispersible tablets 10 mg

INR166

Have any question or need any business consultation?

Contact Us

Have any question or need any business consultation?

Contact Us
Chat with us